The separated Consumer Health Company will take a portfolio of brands in categories including baby care, feminine care, wound care and oral health: covering brands such as Neutrogena, Aveeno, Tylenol, Listerine, Johnson’s and Band-Aid.
The new Johnson & Johnson, meanwhile, will be able to focus on its key pharmaceutical areas and thus ‘remain committed to changing the trajectory of human health’. It highlights its commitments in key therapeutic areas such as oncology and immunology, as well as pledging to continue advancing new therapeutic modalities such as cell and gene therapies.
Pharma-focused company built on strong portfolio and pipeline
J&J says its new pharma-focused company will remain the world’s largest and most diverse healthcare company: blending its pharmaceutical and medical device capabilities. The company will retain treatments such as Darzalex, Erleada, Imbruvica, Stelara, Tremfra and its COVID-19 vaccine.
These pharmaceutical and medical devices segments are expected to generate revenue of approximately $77bn in FY2021.
J&J’s pharmaceutical business focuses on 6 therapeutic areas: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.
J&J highlights the ability of the new company to address diseases in areas such as oncology and eye health that require a combination of surgical, interventional and pharmaceutical treatments.
It also pledges to play leading role in advancing the industry forward by creating novel solutions, bringing together treatments spanning therapeutics, robotics, artificial intelligence and more, to change the way diseases are prevented and intercepted.